Skip to main content
$1.23 -0.02 (-1.21%)

High

$1.29

Low

$1.18

Trades

155

Turnover

$303,224

Volume

249,053
30 June 2023 at 4:10pm
If you were already registered, log in here.

Short Interest

ASIC data, 9 Nov 2026

% Shorted

0.01%
vs 0.01% prior report

Most Shorted Rank

577th
of 711 shorted ASX stocks

Peak Short

0.05%
Dec 2021

Days to Cover

0.2
at 50d avg vol
Subject
RAC Ann: Race investor briefing invitation

RAC Ann: Quarterly Activity Report & Appendix 4C

RAC Ann: Zantrene Protects Mouse Hearts from Chemotherapy Damage

RAC Ann: Zantrene shows synergy with kinase inhibitors in melanoma

RAC Ann: Zantrene Improves Immune Therapy Treatment of Melanoma

RAC Ann: Zantrene data published in Cancer Research Journal

RAC Ann: Notification of buy-back - RAC

RAC Ann: Race Oncology Announces On-Market Share Buyback

RAC Ann: EMD AML MDS Trial Expands to Europe

RAC Ann: Zantrene AML trial in Israel advances to Phase 2

RAC Ann: Trading Halt

RAC Ann: Pause in Trading

RAC Ann: Dr Guy Breitenbucher joins Race SAB

RAC Ann: Appendix 3Y - Mary Harney

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: Appendix 3Y - Phillip Lynch

RAC Ann: Appendix 3Y - Dr John Cullity

RAC Ann: Notification of cessation of securities - RAC

RAC Ann: Race Receives Governance Approval for AML EMD & MDS Trial

RAC Ann: Quarterly Activity Report & Appendix 4C

RAC Ann: CEO & CSO Employment Update

RAC Ann: Becoming a substantial holder

RAC Ann: Race receives Human Ethics AML Trial Approval

RAC Ann: Preclinical & Clinical Programs Update

RAC Ann: Supply Agreement for EMD AML Trial

RAC Ann: Zantrene highly effective in EMD AML Mouse Model

RAC Ann: Race ASX Small and Mid-Cap Conference Presentation

RAC Ann: Compelling Zantrene Preclinical Kidney Cancer Data

RAC Ann: Cleansing Notice

RAC Ann: Application for quotation of securities - RAC

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: Appendix 4D & Half-Year Financial Statements

RAC Ann: MD Anderson Preclinical AML Study on Zantrene Published

RAC Ann: Appointment of Chief Financial Officer

RAC Ann: Quarterly Activity Report & Appendix 4C

RAC Ann: Race Receives FY2021 $708k R&D Tax Refund

RAC Ann: Appendix 3Y - Dr John Cullity

RAC Ann: Ceasing to be a substantial holder

RAC Ann: Ceasing to be a substantial holder

RAC Ann: Change in substantial holding

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: Appendix 3Y - Mary Harney

RAC Ann: Appendix 3Y - Phillip Lynch

RAC Ann: Application for quotation of securities - RAC

RAC Ann: Race raises $29.7 million in oversubscribed SPP

RAC Ann: Change of Registry Address

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: SPP Closing Deadline Reminder & Investor Briefing Recording

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: Uni of Newcastle Heart Protection Collaboration Extended

If you were already registered, log in here.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
TLX
S88
MAV
ATW $7.5m raise
RDO $30m raise
ABC $5m raise
RGS
MBM